- Discussing how the evolution of manufacturing processes and technologies have transformed the biopharmaceutical industry
- When does new manufacturing capabilities generating product innovations, and when does product development spur advances in manufacturing?
- Debating the role new tools, tactics, and technology will have in overcoming the ongoing challenges currently facing the sector
- How should the industry continue to grow and develop the next generation of advanced manufacturing technologies?
Global Head of Operations
Dr. C. Greg Guyer is the Global Head of Operations at BMS. Prior to this he was SVP, Biologics Development & Operations and responsible for overseeing biologics development and operations sites. Greg joined the company in November of 2015. Previously Dr. Guyer spent 21 years in various leadership roles in Merck. His last role was Sr. Vice President, Biologics/Therapeutic Proteins & Sterile Line of Business at Merck. He was responsible for overseeing manufacturing operations for Biologics, Therapeutic Proteins and Sterile Manufacturing Sites. Greg joined the Company in 1994 as Senior Director, Worldwide Regulatory CMC, Merck Research Laboratories. He then held positions of increasing responsibility within the Merck Manufacturing Division (MMD), specifically in the Quality Operations area, Global Quality Assurance and Asia Pacific Operations, until 2005 when he took on the unique role of leading the COMET (Global SAP) Program, a strategic initiative of Merck’s “Plan-to-Win”. He then served as VP, Emerging Markets for MMD leading the development of the Emerging Markets Strategy with his counterparts in Global Human Health and Merck Research Laboratories. Prior to his current role, he was Sr. Vice President, Global Quality overseeing all Quality Operations, Quality Assurance & Research and Commercialization Quality for all lines of our business. Greg is a graduate of the University of Georgia, with advanced degrees from The American University in Washington, DC and Lehigh University. Prior to joining Merck, Greg served in varied capacities over ten years, at the FDA in the Center for Drug Evaluation & Research and also in the Center for Veterinary Medicine.